The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]
Liraglutide FDA Approval Brings First Ever Injectable Weight Loss Drug
Anti-Diabetic, Anti-Obesity Product, FDA Approved 2014 Tags: LiraglutideUnited States Jan 26, 2015
Can Liraglutide Help Patients With PCOS Lose Weight?
Anti-Diabetic, Drug Research & Development API, Patent Expiration 2019 Tags: Liraglutide Oct 22, 2013
Liraglutide CAS No: 204656-20-2 On June 17, 2013 Endocrine Today reported at the ENDO 2013 meeting that Liraglutide demonstrated success as a weight loss treatment. Combined with the antidiabetic drug Metformin, Liraglutide was administered on a short term basis to women with polycystic ovary syndrome who were considered obese. “Obesity is a great problem in[…]
Liraglutide diabetes control is proven and leads to weight loss
Anti-Diabetic, Drug Research & Development API Tags: anti-diabeticDrug AdministrationLiraglutidetype 2 Diabetes Dec 28, 2010
Liraglutide Diabetes Control Liraglutide is a newly developed drug that is used to control the levels of blood glucose in patients suffering from type 2 Diabetes. In January 2010, the US Food and Drug Administration approved this drug for the treatment of patients with diabetes. Liraglutide was approved by the European Medicines Agency (EMEA) in[…]
